Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977060 | 0.87 | EGFR (0.57) | EGFRSMN1; SMN2RAB9AALDH1A1NPC1 | |
| SCHEMBL3979754 | 0.86 | EGFR (0.69) | EGFRRAB9AALDH1A1NPC1MAPT | |
| SCHEMBL8200916 | 0.83 | EGFR (0.57) | EGFRRAB9ANPC1L3MBTL1CSF1R | |
| SCHEMBL17508505 | 0.83 | EGFR (0.54) | EGFRSMN1; SMN2RAB9AALDH1A1NPC1 | |
| SCHEMBL30117773 | 0.82 | RAB9A (0.56) | EGFRSMN1; SMN2RAB9AALDH1A1NPC1 | |
| SCHEMBL7053228 | 0.82 | RAB9A (0.56) | EGFRSMN1; SMN2RAB9AALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL4731344 | 0.82 | EGFR (0.56) | EGFRSMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL3635988 | 0.82 | EGFR (0.62) | EGFRSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL11286630 | 0.81 | RAB9A (0.56) | EGFRSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL4099491 | 0.80 | RAB9A (0.60) | EGFRSMN1; SMN2RAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885SMN1; SMN2 1773/4885RAB9A 920/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | EGFR 3147/4885SMN1; SMN2 1368/4885RAB9A 1178/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2648/4885SMN1; SMN2 1570/4885RAB9A 1077/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885SMN1; SMN2 1773/4885RAB9A 920/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885SMN1; SMN2 1773/4885RAB9A 920/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | EGFR 2915/4885SMN1; SMN2 1773/4885RAB9A 920/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885SMN1; SMN2 1773/4885RAB9A 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.